U.S. pharmaceutical companies are expected to collect more revenue from COVID-19 vaccines in the third quarter than they did in the entire first half of the year, and that money should continue to grow.
In the first half of the year, Pfizer Inc. PFE and Moderna Inc. MRNA reported collective sales of $17.2 billion for their vaccines, but both are expected to report higher third-quarter totals in the coming week, a collective $18 billion. Pfizer is scheduled to report earnings Tuesday morning, while Moderna follows on Thursday…
This post was originally published on Market Watch
